Relief of Pain and Inflammation : Narcotic Analgesics
OSUBO3 “Suboxone SL tablet”
Each tablet contains buprenorphine HCl 2.16 mg, naloxone HCl 0.61 mg; 2 mg/tab
OSUBO4 “Suboxone SL tablet”
Each tablet contains buprenorphine HCl 8.64 mg, naloxone HCl2.44 mg; 8 mg/tab
適應症：鴉片類物質成癮之替代療法。
Usual dose:
Opioid dependence: maintenance, 12 -16 mg/day PO SL; adjust dosage in 2-4 mg increments/decrements to level that holds patient in treatment and suppresses opioid withdrawal effects; typical range 4-24 mg/day.
Dose adjustment:
Hepatic impairment: dosage reduction, watch patient for symptoms of precipitated opioid withdrawal.
Precaution:
Concomitant CYP3A4 inhibitors, dose adjustment recommended.
Adverse effect:
Sweating symptom, abdominal pain, constipation, nausea, vomiting, headache. The most common treatment-related adverse events reported during clinical trials with Suboxone were those related to withdrawal symptoms (e.g., abdominal pain, diarrhea, muscle aches, anxiety, sweating).